An unbalanced inflammatory cytokine response is not associated with mortality following sepsis: A prospective cohort study

Critical Care Medicine

Volumn 45, Issue 5, 2017, Pages e493-e499

  Frencken, Jos F ^a   Van Vught, Lonneke A ^b,c   Peelen, Linda M ^a   Ong, David S Y ^a   Klouwenberg, Peter M C Klein ^a   Horn, Janneke ^d   Bonten, Marc J M ^a   Van Der Poll, Tom ^b,c   Cremer, Olaf L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Center for Infection and Immunity   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anti inflammatory; Balance; Host response; Proinflammatory; Sepsis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; CYTOKINE; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CATHETER; CATHETER INFECTION; COHORT ANALYSIS; CYTOKINE RESPONSE; CYTOMETRY; DISEASE ASSOCIATION; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SEPSIS; SEPTIC SHOCK; APACHE; CLINICAL TRIAL; CROSS INFECTION; HOSPITAL MORTALITY; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

AGED; APACHE; CROSS INFECTION; CYTOKINES; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; SHOCK, SEPTIC; TIME FACTORS;

EID: 85014274124     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002292     Document Type: Article

References (35)

1. Bone RC: Sepsis syndrome. New insights into its pathogenesis and treatment. Infect Dis Clin North Am 1991; 5:793-805.
2. Bone RC: The pathogenesis of sepsis. Ann Intern Med 1991; 115:457-469.
3. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
4. Cohen J, Vincent JL, Adhikari NK, et al: Sepsis: A roadmap for future research. Lancet Infect Dis 2015; 15:581-614.
5. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150.
6. Marshall JC: Why have clinical trials in sepsis failed? Trends Mol Med 2014; 20:195-203.
7. van der Poll T, Opal SM: Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43.
8. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13:862-874.
9. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13:260-268.
10. Winters BD, Eberlein M, Leung J, et al: Long-Term mortality and quality of life in sepsis: A systematic review. Crit Care Med 2010; 38:1276-1283.
11. Yende S, D'Angelo G, Kellum JA, et al; GenIMS Investigators: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177:1242-1247.
12. Klein Klouwenberg PM, Ong DS, Bos LD, et al: Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med 2013; 41:2373-2378.
13. Klein Klouwenberg PM, Cremer OL, van Vught LA, et al: Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: A cohort study. Crit Care 2015; 19:319.
14. Singer M, Deutschman CS, Seymour CW, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801-810.
15. Hamers L, Kox M, Pickkers P: Sepsis-induced immunoparalysis: Mechanisms, markers, and treatment options. Minerva Anestesiol 2015; 81:426-439.
16. Schaper F, Rose-John S: Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 2015; 26:475-487.
17. Andaluz-Ojeda D, Bobillo F, Iglesias V, et al: A combined score of pro-And anti-inflammatory interleukins improves mortality prediction in severe sepsis. Cytokine 2012; 57:332-336.
18. Tamayo E, Fernández A, Almansa R, et al: Pro-And anti-inflammatory responses are regulated simultaneously from the first moments of septic shock. Eur Cytokine Netw 2011; 22:82-87.
19. van der Poll T, de Waal Malefyt R, Coyle SM, et al: Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997; 175:118-122.
20. Bozza FA, Salluh JI, Japiassu AM, et al: Cytokine profiles as markers of disease severity in sepsis: A multiplex analysis. Crit Care 2007; 11:R49.
21. Brivet FG, Emilie D, Galanaud P: Pro-And anti-inflammatory cytokines during acute severe pancreatitis: An early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit Care Med 1999; 27:749-755.
22. Hotchkiss RS, Coopersmith CM, McDunn JE, et al: The sepsis seesaw: Tilting toward immunosuppression. Nat Med 2009; 15:496-497.
23. Zou G: A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702-706.
24. Kellum JA, Kong L, Fink MP, et al; GenIMS Investigators: Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167:1655-1663.
25. Gomez HG, Gonzalez SM, Londoño JM, et al: Immunological characterization of compensatory anti-inflammatory response syndrome in patients with severe sepsis: A longitudinal study. Crit Care Med 2014; 42:771-780.
26. Gogos C, Kotsaki A, Pelekanou A, et al: Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 2010; 14:R96.
27. Royston P, Sauerbrei W: In: Multivariable Model-Building. A Pragmatic Approach Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, John Wiley and Sons, 2008, pp 172-181.
28. Kohl M, Plischke M, Leffondré K, et al: PSHREG: A SAS macro for proportional and nonproportional subdistribution hazards regression. Comput Methods Programs Biomed 2015; 118:218-233.
29. Leentjens J, Kox M, van der Hoeven JG, et al: Immunotherapy for the adjunctive treatment of sepsis: From immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med 2013; 187:1287-1293.
30. Monneret G, Finck ME, Venet F, et al: The anti-inflammatory response dominates after septic shock: Association of low monocyte HLADR expression and high interleukin-10 concentration. Immunol Lett 2004; 95:193-198.
31. Leonidou L, Mouzaki A, Michalaki M, et al: Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. J Infect 2007; 55:340-346.
32. Osuchowski MF, Welch K, Siddiqui J, et al: Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006; 177:1967-1974.
33. Osuchowski MF, Craciun F, Weixelbaumer KM, et al: Sepsis chronically in MARS: Systemic cytokine responses are always mixed regardless of the outcome, magnitude, or phase of sepsis. J Immunol 2012; 189:4648-4656.
34. Umberger R, Thompson CL, Cashion AK, et al: Exaggerated plasma interleukin 6, interleukin 10, and subsequent development of health care-Associated infections in patients with sepsis. Dimens Crit Care Nurs 2015; 34:100-111.
35. Oostdijk EA, de Smet AM, Kesecioglu J, et al; Dutch SOD-SDD Trialists Group: The role of intestinal colonization with gram-negative bacteria as a source for intensive care unit-Acquired bacteremia. Crit Care Med 2011; 39:961-966.